Drugs / ABDAVOMERAN
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04523571 | Jul → Sep 2020 | COVID-19 | BioNTech SE | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04380701 | Apr 2020 → Jun 2021 | respiratory tract infectious disorder, viral infectious disease | BioNTech SE | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04368728 | Apr 2020 → Feb 2023 | COVID-19 | BioNTech SE | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-09-30 | BioNTech SE | BioNTech and Pfizer Announce Nature Publication of German Phase 1/2 Study Data from mRNA-based Vaccine Candidate BNT162b1 Against SARS-CoV-2 biontech.com ↗ |
| 2020-08-12 | BioNTech SE | Pfizer and BioNTech Announce Publication of Peer-Reviewed Data from Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate, BNT162b1, Against SARS-CoV-2 in Nature biontech.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABDAVOMERAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650454 ↗ |
| Known as | BNT162b1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04380701 ↗ |
| Modality | Messenger RNA (mRNA) | “BNT162b1 is a lipid-nanoparticle-formulated, nucleoside-modified mRNA vaccine” PMID 32785213 ↗ Aug 2020 |
| Route | Intramuscular | “Intramuscular injection” NCT04368728 ↗ |